SEC Form 3 · accession 0001144204-19-009923
TITAN PHARMACEUTICALS INC · TTNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katherine Beebe
Officer — Chief Scientific Officer
Period of report
Feb 19, 2019
Accepted (ET)
Feb 25, 2019 · 5:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000910267
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 2,387 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (Right to Buy)F1 | $1.56 | holding | — | — | — | — | — | Common Stock | 28,487 | — | D |
| Option (Right to Buy)F2 | $19.80 | holding | — | — | — | — | Mar 16, 2025 | Common Stock | 4,243 | — | D |
| Option (Right to Buy)F3 | $5.82 | holding | — | — | — | — | Mar 7, 2028 | Common Stock | 28,335 | — | D |
Explanation of responses
- F1Represents currently vested options that were granted between May 2009 and February 2017 that were repriced effective January 23, 2019. Of such options, 7,576 expire on May 17, 2019, with the balance expiring on various dates between May 11, 2021 and February 13, 2027.
- F2These options, which were granted in March 2015, are fully vested.
- F3These options, which were granted in March 2017, are fully vested.